What I'm reading, what I'm drinking.
Two of these things are not long for this world -- the paper book and the paper newspaper.
And yet, coffee and good story will last forever.
The book is a novel of the Civil War with the kind of granularity in detail that makes my own brain spark.
The newspaper too has a few interests. The lead story today is on pharma fraud, and though none of the key players are actually named, I know them all.
For years, a trio of anemia drugs known as Epogen, Procrit and Aranesp ranked among the best-selling prescription drugs in the United States, generating more than $8 billion a year for two companies, Amgen and Johnson & Johnson. Even compared with other pharmaceutical successes, they were superstars. For several years, Epogen ranked as the single costliest medicine under Medicare: U.S. taxpayers put up as much as $3 billion a year for the drugs..
The trouble, as a growing body of research has shown, is that for about two decades, the benefits of the drug — including “life satisfaction and happiness” according to the FDA-approved label — were wildly overstated, and potentially lethal side effects, such as cancer and strokes, were overlooked.... ..,[A]t the center of any explanation of the popularity of these drugs are the nation’s doctors, clinics and hospitals, and the choices they made for patients.
Americans might like to think that doctors focus on only their health. But physicians and hospitals have to pay the bills, too, and, in some cases, the more they treat a patient, the more they earn. This was especially true in the case of the anemia drugs: The bigger the dose, the more they made.
No comments:
Post a Comment